Your browser is no longer supported. Please, upgrade your browser.
Lumos Pharma, Inc.
Index- P/E- EPS (ttm)-1.77 Insider Own9.70% Shs Outstand8.32M Perf Week-1.17%
Market Cap61.41M Forward P/E- EPS next Y-4.78 Insider Trans0.00% Shs Float6.27M Perf Month-24.00%
Income-14.60M PEG- EPS next Q-1.04 Inst Own40.10% Short Float0.58% Perf Quarter-38.61%
Sales0.10M P/S614.08 EPS this Y91.00% Inst Trans0.28% Short Ratio1.03 Perf Half Y-55.81%
Book/sh13.10 P/B0.58 EPS next Y-12.20% ROA-10.50% Target Price- Perf Year-45.75%
Cash/sh14.12 P/C0.54 EPS next 5Y15.20% ROE-12.70% 52W Range7.36 - 36.72 Perf YTD-78.72%
Dividend- P/FCF- EPS past 5Y40.70% ROI-10.60% 52W High-79.30% Beta1.66
Dividend %- Quick Ratio24.00 Sales past 5Y-69.90% Gross Margin- 52W Low3.26% ATR0.41
Employees28 Current Ratio24.00 Sales Q/Q- Oper. Margin- RSI (14)22.98 Volatility4.16% 4.50%
OptionableNo Debt/Eq0.00 EPS Q/Q-630.70% Profit Margin- Rel Volume16.07 Prev Close7.36
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume35.41K Price7.60
Recom1.70 SMA20-16.49% SMA50-24.71% SMA200-47.60% Volume456,912 Change3.26%
Mar-11-21Upgrade Stifel Hold → Buy $4 → $24
Dec-03-20Initiated Cantor Fitzgerald Buy $32
Aug-26-20Initiated Piper Sandler Overweight $26
Aug-17-20Resumed ROTH Capital Buy $51
Aug-04-20Initiated H.C. Wainwright Buy $33
Jul-26-21 04:18PM  
Jul-22-21 08:00AM  
Jul-20-21 04:01PM  
Jun-28-21 08:00AM  
May-19-21 09:00AM  
May-13-21 09:00AM  
May-05-21 04:01PM  
Apr-28-21 09:00AM  
Apr-27-21 08:00AM  
Apr-20-21 04:05PM  
Apr-14-21 04:05PM  
Mar-20-21 11:00AM  
Mar-11-21 04:05PM  
Mar-09-21 04:05PM  
Mar-04-21 09:00AM  
Mar-02-21 04:05PM  
Feb-22-21 04:15PM  
Feb-16-21 04:01PM  
Dec-18-20 09:00AM  
Dec-16-20 02:19AM  
Nov-30-20 05:35PM  
Nov-23-20 07:43PM  
Nov-10-20 04:01PM  
Nov-03-20 12:30PM  
Oct-29-20 09:00AM  
Oct-27-20 04:01PM  
Aug-27-20 09:00AM  
Aug-13-20 04:01PM  
Jul-28-20 04:01PM  
Jul-27-20 04:05PM  
Jun-19-20 08:21AM  
Jun-10-20 03:41PM  
May-28-20 04:01PM  
May-27-20 04:27PM  
May-26-20 10:36AM  
Apr-24-20 08:00AM  
Apr-02-20 04:05PM  
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James E10% OwnerJan 08Sale22.31106,5122,376,099784,568Jan 08 05:54 PM
Flynn James E10% OwnerJan 07Sale24.5416,172396,821891,080Jan 08 05:54 PM
Flynn James E10% OwnerJan 06Sale22.4829,039652,703907,252Jan 08 05:54 PM